Pasithea Issuance Of Capital Stock vs Begin Period Cash Flow Analysis
| KTTA Stock | USD 2.52 0.14 5.26% |
Pasithea Therapeutics financial indicator trend analysis is much more than just breaking down Pasithea Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Pasithea Therapeutics is a good investment. Please check the relationship between Pasithea Therapeutics Issuance Of Capital Stock and its Begin Period Cash Flow accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Pasithea Therapeutics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
Issuance Of Capital Stock vs Begin Period Cash Flow
Issuance Of Capital Stock vs Begin Period Cash Flow Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Pasithea Therapeutics Issuance Of Capital Stock account and Begin Period Cash Flow. At this time, the significance of the direction appears to have pay attention.
The correlation between Pasithea Therapeutics' Issuance Of Capital Stock and Begin Period Cash Flow is -0.96. Overlapping area represents the amount of variation of Issuance Of Capital Stock that can explain the historical movement of Begin Period Cash Flow in the same time period over historical financial statements of Pasithea Therapeutics Corp, assuming nothing else is changed. The correlation between historical values of Pasithea Therapeutics' Issuance Of Capital Stock and Begin Period Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Issuance Of Capital Stock of Pasithea Therapeutics Corp are associated (or correlated) with its Begin Period Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Begin Period Cash Flow has no effect on the direction of Issuance Of Capital Stock i.e., Pasithea Therapeutics' Issuance Of Capital Stock and Begin Period Cash Flow go up and down completely randomly.
Correlation Coefficient | -0.96 |
| Relationship Direction | Negative |
| Relationship Strength | Significant |
Issuance Of Capital Stock
Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Most indicators from Pasithea Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Pasithea Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Pasithea Therapeutics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. At present, Pasithea Therapeutics' Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Issuance Of Capital Stock is expected to grow to about 31 M, whereas Sales General And Administrative To Revenue is forecasted to decline to 16.32.
| 2010 | 2022 | 2023 | 2024 (projected) | Reconciled Depreciation | 1.4K | 32.4K | 517.7K | 543.5K | Cost Of Revenue | 17.3K | 113.2K | 648.5K | 680.9K |
Pasithea Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Pasithea Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Pasithea Therapeutics is a strong investment it is important to analyze Pasithea Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Pasithea Therapeutics' future performance. For an informed investment choice regarding Pasithea Stock, refer to the following important reports:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Pasithea Therapeutics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pasithea Therapeutics. If investors know Pasithea will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pasithea Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (14.79) | Revenue Per Share 0.37 | Quarterly Revenue Growth 14.981 | Return On Assets (0.38) | Return On Equity (0.63) |
The market value of Pasithea Therapeutics is measured differently than its book value, which is the value of Pasithea that is recorded on the company's balance sheet. Investors also form their own opinion of Pasithea Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Pasithea Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pasithea Therapeutics' market value can be influenced by many factors that don't directly affect Pasithea Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pasithea Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Pasithea Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pasithea Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.